DocuSign Results Dispel Fears Around Billings
DocuSign (NASDAQ: DOCU) has been among the group of companies that inadvertently benefited from the COVID-19 pandemic this year. The public health crisis accelerated adoption of its core electronic signature products as businesses had to adapt to unprecedented conditions while maintaining productivity and digitally inking paperwork.
But investors weren't too impressed with the company's second-quarter release in early September -- mostly due to concerns around billings deceleration -- causing shares to reach record highs only to immediately pull back. The electronic signature specialist just put those fears to rest.
Image source: DocuSign.
Source Fool.com
